Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Conmed's Total Liabilities for the quarter that ended in Jun. 2026 was $1,259 Mil.
Conmed's quarterly Total Liabilities
increased
from Dec. 2025 ($1,292.65 Mil) to Mar. 2026 ($1,297.27 Mil) but then
declined
from Mar. 2026 ($1,297.27 Mil) to Jun. 2026 ($1,258.92 Mil).
Conmed's annual Total Liabilities
declined
from Dec. 2023 ($1,465.80 Mil) to Dec. 2024 ($1,343.57 Mil) and
declined
from Dec. 2024 ($1,343.57 Mil) to Dec. 2025 ($1,292.65 Mil).
The historical data trend for Conmed's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Conmed's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Conmed (CNMD) has a Total Liabilities of $1,259 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Conmed and its competitors.
Is Conmed's Total Liabilities too high?
Conmed's current Total Liabilities is $1,259 Mil. Overall, Conmed has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Conmed's Total Liabilities compare to ATEC and AORT?
Conmed's Total Liabilities of $1,259 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Conmed and its competitors. Conmed's current Total Liabilities is $1,259 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Conmed stock overvalued right now?
Based on GuruFocus' analysis, Conmed (CNMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $67.46, compared to a current price of $51.54 — trading 23.6% below its estimated fair value. The current Total Liabilities is $1,259 Mil. Conmed's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Conmed (CNMD), the current Total Liabilities is $1,259 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Conmed (CNMD) Overvalued in 2026?
Based on GuruFocus' analysis, Conmed stock appears to be undervalued.
The current stock price of $51.54 is trading 23.6% below its estimated GF Value™ of $67.46.
GuruFocus considers Conmed to be Modestly Undervalued.
Key valuation signals for CNMD:
Total Liabilities: $1,259 Mil
GF Value™: $67.46 vs. price of $51.54 (23.6% below fair value)
No single metric tells the full story. See the CNMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
80GF Score
Get the complete analysis for CNMD
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CNMD has been successfully added to your 
